Previous 10 | Next 10 |
NEW YORK, NY / ACCESSWIRE / February 10, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Inhibrx, Inc. (NASDAQ: INBX)'s...
NEW YORK, NY / ACCESSWIRE / January 27, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to Inhibrx, Inc. (NASDAQ: INBX)'s sa...
NEW YORK, NY / ACCESSWIRE / January 26, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Kaman Corp. (NYSE:KAMN)'s sale t...
NEW YORK, NY / ACCESSWIRE / January 25, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Inhibrx, Inc. (NASDAQ:INBX)'s sa...
2024-01-24 09:00:58 ET Summary Sanofi acquires INBRX-101 from Inhibrx for $2.2 billion, targeting rare disease Alpha-1 Antitrypsin Deficiency (AATD). INBRX-101's monthly dosing offers a potential improvement over weekly treatments in AATD, with a novel AAT-Fc fusion approach. ...
2024-01-23 04:42:01 ET In a bid to strengthen its rare disease portfolio, Sanofi ( NASDAQ: SNY ) has agreed to acquire certain assets from biopharmaceutical company Inhibrx ( NASDAQ: INBX ) in a deal valued at up to $2.2B.... Read the full article on Seeking Alpha ...
Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B PR Newswire Inhibrx, Inc. shareholders will receive per share consideration of $30 per share in cash, a CVR equal to $5 , plus 0.25 shares in New Inhibrx, a new publicly traded company ...
2024-01-19 20:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-12-14 13:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-11-10 10:31:32 ET More on Inhibrx Seeking Alpha's Quant Rating on Inhibrx Historical earnings data for Inhibrx For further details see: Inhibrx posts Q3 results
News, Short Squeeze, Breakout and More Instantly...
Inhibrx Inc. Company Name:
INBX Stock Symbol:
NASDAQ Market:
Smart Share Global Limited (EM) is expected to report for Q1 2024 American Rebel Holdings Inc. (AREB) is expected to report for Q1 2024 First Republic Bank (San Francisco, California) (FRCB) is expected to report for Q1 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ...
Inhibrx Biosciences Inc. (INBX) is expected to report for Q1 2024
2024-05-31 21:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...